down arrow

Astrazeneca Phar

Part of MojoOne Strategy
  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Drugs
  • ISIN: INE203A01020
  • NSEID: ASTRAZEN
  • BSEID: 506820
INR
8,388.95
385.05 (4.81%)
BSENSE

Apr 11, 12:53 PM

BSE+NSE Vol: 18.23 k

Click here to access the older version
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

8,149.958,460.65

52 Week

5,000.009,049.95
Valuation
Technical
Day's Volume

CASH

18.23 k (-31.57%) Volume

Shareholding (Dec 2024)

FII

2.93%

Held by 95 FIIs

DII

5.22%

Held by 8 DIIs

Promoter

75.00%

iScoreScore
Part of MojoOne Strategy
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Dashboard
1

High Management Efficiency with a high ROE of 19.06%

 
2

Company has a low Debt to Equity ratio (avg) at 0 times

 
3

With a growth in Operating Profit of 40.01%, the company declared Very Positive results in Dec 24

4

Stock is technically in a Mildly Bullish range

5

Majority shareholders : Promoters

 
6

Company is among the highest 1% of companies rated by MarketsMojo across all 4,000 stocks

 
7

Consistent Returns over the last 3 years

stock-summaryMojo Parameters
Mojo Parameters
Loading Valuation Snapshot...
Stock DNA
stock-summary
Industry

Pharmaceuticals & Drugs

stock-summary
Market cap

INR 20,972 Cr (Large Cap)

stock-summary
P/E

112.00

stock-summary
Industry P/E

33

stock-summary
Dividend Yield

0.30%

stock-summary
Debt Equity

-0.70

stock-summary
Return on Equity

25.17%

stock-summary
Price to Book

28.11

Revenue and Profits (1 Year):
Net Sales:
440 Cr
(Quarterly Results - Dec 2024)
Net Profit:
31 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0.3%)
TimePeriod
Price Return
Dividend Return
Total Return
6 Months
8.51%
0%
8.51%
1 Year
55.8%
0.45%
56.25%
2 Years
157.26%
1.25%
158.51%
3 Years
192.97%
1.96%
194.93%
4 Years
153.08%
1.32%
154.4%
5 Years
213.88%
1.66%
215.54%

Latest dividend: 24 per share ex-dividend date: Jul-05-2024

Risk Adjusted Returns v/s Sensex stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
14.37%
EBIT Growth (5y)
15.15%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
1.92
Tax Ratio
26.68%
Dividend Payout Ratio
37.15%
Pledged Shares
0
Institutional Holding
8.15%
ROCE (avg)
99.35%
ROE (avg)
19.06%
Valuation key factors
Factor
Value
P/E Ratio
112
Industry P/E
33
Price to Book Value
28.11
EV to EBIT
102.18
EV to EBITDA
89.91
EV to Capital Employed
92.60
EV to Sales
12.05
PEG Ratio
8.09
Dividend Yield
0.30%
ROCE (Latest)
80.46%
ROE (Latest)
25.17%
Tecnicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 40 Schemes (5.04%)

FIIs

Held by 95 FIIs (2.93%)

Promoter with highest holding

Astrazeneca Pharmaceuticals Ab (75.0%)

Highest Public shareholder

Nippon Life (various Schemes) (2.92%)

Individual Investors Holdings

14.62%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Dec'24 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2024 is 7.91% vs 5.28% in Sep 2024",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2024 is -19.72% vs 425.95% in Sep 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "440.29",
          "val2": "408.00",
          "chgp": "7.91%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "76.99",
          "val2": "52.54",
          "chgp": "46.54%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.33",
          "val2": "0.34",
          "chgp": "-2.94%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-33.55",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "30.85",
          "val2": "38.43",
          "chgp": "-19.72%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "17.49%",
          "val2": "12.88%",
          "chgp": "4.61%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2024 is 31.16% vs 29.48% in Sep 2023",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": " Growth in half year ended Sep 2024 is -74.92% vs 101.50% in Sep 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'24",
        "Sep'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "795.52",
          "val2": "606.54",
          "chgp": "31.16%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "90.61",
          "val2": "120.00",
          "chgp": "-24.49%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.45",
          "val2": "0.65",
          "chgp": "-30.77%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-57.56",
          "val2": "16.43",
          "chgp": "-450.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "26.64",
          "val2": "106.23",
          "chgp": "-74.92%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "11.39%",
          "val2": "19.78%",
          "chgp": "-8.39%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Standalone) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2024 is 35.46% vs 27.02% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2024 is -52.89% vs 48.78% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,235.81",
          "val2": "912.33",
          "chgp": "35.46%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "167.60",
          "val2": "135.05",
          "chgp": "24.10%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.78",
          "val2": "1.26",
          "chgp": "-38.10%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-91.11",
          "val2": "16.43",
          "chgp": "-654.53%",
          "chgp_class": "negative"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "57.49",
          "val2": "122.03",
          "chgp": "-52.89%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "13.56%",
          "val2": "14.80%",
          "chgp": "-1.24%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2024 is 29.17% vs 24.50% in Mar 2023",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2024 is 62.66% vs 61.21% in Mar 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'24",
        "Mar'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,295.53",
          "val2": "1,002.97",
          "chgp": "29.17%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "184.45",
          "val2": "165.12",
          "chgp": "11.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.20",
          "val2": "0.63",
          "chgp": "90.48%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "16.43",
          "val2": "-40.23",
          "chgp": "140.84%",
          "chgp_class": "positive"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "161.51",
          "val2": "99.29",
          "chgp": "62.66%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "14.24%",
          "val2": "16.46%",
          "chgp": "-2.22%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Standalone) - Dec'24 - QoQstock-summary
Dec'24
Sep'24
Change(%)
Net Sales
440.29
408.00
7.91%
Operating Profit (PBDIT) excl Other Income
76.99
52.54
46.54%
Interest
0.33
0.34
-2.94%
Exceptional Items
-33.55
0.00
Standalone Net Profit
30.85
38.43
-19.72%
Operating Profit Margin (Excl OI)
17.49%
12.88%
4.61%
Values in Rs Cr.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Dec 2024 is 7.91% vs 5.28% in Sep 2024

Direction Arrows
Standalone Net Profit

QoQ Growth in quarter ended Dec 2024 is -19.72% vs 425.95% in Sep 2024

All Quarterly Resultsstock-summary
Half Yearly Results Snapshot (Standalone) - Sep'24stock-summary
Sep'24
Sep'23
Change(%)
Net Sales
795.52
606.54
31.16%
Operating Profit (PBDIT) excl Other Income
90.61
120.00
-24.49%
Interest
0.45
0.65
-30.77%
Exceptional Items
-57.56
16.43
-450.33%
Standalone Net Profit
26.64
106.23
-74.92%
Operating Profit Margin (Excl OI)
11.39%
19.78%
-8.39%
Values in Rs Cr.
stock-summary Compare with Peers
Direction Arrows
Net Sales

Growth in half year ended Sep 2024 is 31.16% vs 29.48% in Sep 2023

Direction Arrows
Standalone Net Profit

Growth in half year ended Sep 2024 is -74.92% vs 101.50% in Sep 2023

All Half Yearly Resultsstock-summary
Nine Monthly Results Snapshot (Standalone) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
1,235.81
912.33
35.46%
Operating Profit (PBDIT) excl Other Income
167.60
135.05
24.10%
Interest
0.78
1.26
-38.10%
Exceptional Items
-91.11
16.43
-654.53%
Standalone Net Profit
57.49
122.03
-52.89%
Operating Profit Margin (Excl OI)
13.56%
14.80%
-1.24%
Values in Rs Cr.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in nine months ended Dec 2024 is 35.46% vs 27.02% in Dec 2023

Direction Arrows
Standalone Net Profit

YoY Growth in nine months ended Dec 2024 is -52.89% vs 48.78% in Dec 2023

All Nine Monthly Resultsstock-summary
Annual Results Snapshot (Standalone) - Mar'24stock-summary
Mar'24
Mar'23
Change(%)
Net Sales
1,295.53
1,002.97
29.17%
Operating Profit (PBDIT) excl Other Income
184.45
165.12
11.71%
Interest
1.20
0.63
90.48%
Exceptional Items
16.43
-40.23
140.84%
Standalone Net Profit
161.51
99.29
62.66%
Operating Profit Margin (Excl OI)
14.24%
16.46%
-2.22%
Values in Rs Cr.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2024 is 29.17% vs 24.50% in Mar 2023

Direction Arrows
Standalone Net Profit

YoY Growth in year ended Mar 2024 is 62.66% vs 61.21% in Mar 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Astrazeneca Pharma India Ltd stock-summary
stock-summary
Astrazeneca Pharma India Ltd
Large Cap
Pharmaceuticals & Drugs
AstraZeneca Pharma India (APIL) was incorporated on July 11, 1979. The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company. The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology.
Company Coordinates stock-summary
Company Details
Blk N1 12th Flr Manyata Embass, Rachenahalli Outer Ring Road Bangalore Karnataka : 560045
stock-summary
Tel: 91-080-67748000
stock-summary
http://www.astrazeneca.in
stock-summary
comp.secy@astrazeneca.com
Registrar Details
Integrated Enterprises (India) Ltd , 30, Ramana Residency, 4th Cross, Sampige Road, Malleswaram, Bangalore
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."